Holen Sie sich die Stockscreener-App
30.61
4.73%
-1.52
Handel nachbörslich:
31.05
0.44
+1.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Unusual Options Activity - Nasdaq
Cytokinetics gets an ‘incremental’ win for delayed heart drug - Endpoints News
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Cytokinetics stock rises on Phase 3 trial win (CYTK:NASDAQ) - Seeking Alpha
Cytokinetics (CYTK) Reports Positive Results from Phase 3 Clinical Trial | CYTK Stock News - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | CYTK Stock News - GuruFocus
Aficamten outperforms beta blocker in HCM trial - Investing.com
Cytokinetics' heart disease drug meets main goal in late-stage study - marketscreener.com
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - Eagle-Tribune
Dimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
5,400 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Raymond James Financial Inc. - Defense World
Cytokinetics, Incorporated Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- CYTK - ACCESS Newswire
FY2025 EPS Estimates for Cytokinetics Lowered by Analyst - Defense World
Barclays Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $53.00 - Defense World
HC Wainwright Has Weak Estimate for Cytokinetics Q2 Earnings - Defense World
What is B. Riley’s Estimate for Cytokinetics Q2 Earnings? - Defense World
Leerink Partnrs Predicts Lower Earnings for Cytokinetics - Defense World
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Royal Bank of Canada Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress - Stock Titan
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Cytokinetics (CYTK) Maintains Overweight Rating Despite Price Target Cut | CYTK Stock News - GuruFocus
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating - marketscreener.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cytokinetics shares hold as JMP reiterates $78 price target By Investing.com - Investing.com Nigeria
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month Low Following Analyst Downgrade - Defense World
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights By Investing.com - Investing.com Nigeria
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
CYTK: Citigroup Lowers Price Target for Cytokinetics | CYTK Stoc - GuruFocus
Cytokinetics Inc earnings beat by $0.01, revenue fell short of estimates - Investing.com Nigeria
Cytokinetics to Hold Annual Meeting of Stockholders - Stock Titan
Cytokinetics (CYTK) Price Target Adjusted by RBC Capital | CYTK Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended - Yahoo Finance
Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook - Seeking Alpha
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com Australia
Cytokinetics (CYTK) Price Target Adjusted as FDA Decision Delayed | CYTK Stock News - GuruFocus
Cytokinetics shares hold as JMP reiterates $78 price target - Investing.com
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges By GuruFocus - Investing.com Canada
Cytokinetics (CYTK) Advances Aficamten Commercialization Plans - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics: Q1 Earnings Snapshot - The Washington Post
Cytokinetics (CYTK) Misses Q1 Revenue Estimates and Advances Car - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings: EPS of -$1.36 Beats Es - GuruFocus
Earnings call transcript: Cytokinetics reports Q1 2025 net loss, stock dips - Investing.com India
Cytokinetics Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Cytokinetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (CYTK) Cytokinetics Q1 Loss $1.36 Vs. FactSet Est. Loss $1.37 - marketscreener.com
Cytokinetics shares fall as Q1 revenue misses estimates By Investing.com - Investing.com Canada
Cytokinetics Inc (CYTK) Q1 2025 Earnings: EPS of -$1.36 Beats Estimate, Revenue Surpasses Forecast at $1.6 Million - GuruFocus
CYTOKINETICS Earnings Results: $CYTK Reports Quarterly Earnings - Nasdaq
FDA Pushes Cytokinetics' Key HCM Drug Review to December: What This PDUFA Extension Means for Patients - Stock Titan
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):